Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa

Clinical Infectious Diseases

Volumn 38, Issue 6, 2004, Pages 851-856

  Patel, V B ^a   Padayatchi, N ^a   Bhigjee, A I ^a   Allen, J ^b   Bhagwan, B ^a   Moodley, A A ^a   Mthiyane, T ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PREDNISONE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SOUTH AFRICA; TUBERCULOUS MENINGITIS; ARTICLE; CASE REPORT; CHILD; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHYSIOLOGY; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 1642417402     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381973     Document Type: Review

References (26)

1. World Health Organization. WHO annual report on global tuberculosis - summary. Wkly Epidemiol Rec 2003; 78:122-8.
2. World Health Organization (WHO). Global tuberculosis control report 2003: profiles of high burden countries. Geneva: WHO, 2003.
3. Weyer K, Lancaster J, Brand J, Van der Walt M, Levin J. Survey of tuberculous drug resistance in South Africa, 2001-2002: technical report to the Department of Health. Pretoria, South Africa: Medical Research Council of South Africa, 2003.
4. Hopewell PC. Overview of clinical tuberculosis. In: Barry R. Bloom, ed. Tuberculosis pathogenesis, protection and control. Washington, DC: American Society for Microbiology, 1994:40-1.
5. Schutte CM. Clinical and epidemiological study: clinical, cerebrospinal fluid changes, pathological findings and outcomes in HIV-positive and HIV-negative patients with tuberculous meningitis. Infection 2001; 29:213-7.
6. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world, report no. 2: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/CDS/TB/2000.278. Geneva: WHO, 2000.
7. Daikos GL, Cleary T, Rodriguez A, Fischl MA. Multidrug-resistant tuberculous meningitis in patients with AIDS. Int J Tuberc Lung Dis 2003; 7:394-8.
8. Sofia M, Marisclaco M, Honora N, Molino A, Heym B, Cole T. Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Int J Tuberc Lung Dis 2001; 5:551-8.
9. Silber G, Sonenberg P, Saffer D, Koornhof H. Multidrug-resistant tuberculous meningitis in a health care worker. Int J Tuberc Lung Dis 1998; 2:774.
10. Souza RD, Franklin D, Simpson J, Kerr F. Atypical presentation of tuberculosis meningitis: a case report. Scott Med J 2002; 47:14-8.
11. World Health Organization (WHO). Guidelines on the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva: WHO, 1996.
12. Churchyard GJ, Kleinschmidt I, Corbett EL, Mulder D, Smit J, De Kock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4:705-12.
13. Colvin M, Dawood S, Kleinschmidt I, Mullick S, Lalloo U. Prevalence of HIV and HIV-related disease on the adult medical wards of a tertiary hospital in Durban, South Africa. Int J STD AIDS 2001; 12:386-9.
14. De Kock KM, Wilkinson D. Tuberculosis control in resource-poor countries: alternative strategies in the era of HIV. Lancet 1995; 346:675-7.
15. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis and treatment. Bull WHO 1992; 70:515-26.
16. Schluger NW. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected participants. Clin Infect Dis 1999; 28:130-5.
17. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus." BMJ 1998; 317:671-4.
18. Thwaites GE, Chau TT, Mai NT, et al. Tuberculous meningitis. J Neurol Neurosurg Psychiatry 2000; 68:807-23.
19. Ellard GA, Humphries MJ, Allen WA. Cerebrospinal fluid drug concentrations and treatment of tuberculous meningitis. Am Rev Respir Dis 1993; 148:650-5.
20. Peloquin CA. Pharmacology of antimycobacterial drugs. Med Clin North Am 1993; 77:1253-62.
21. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21(Suppl 10):233s-252s.
22. Berger JR. Tuberculous meningitis. Curr Opin Neurol 1994; 7:191-200.
23. Patel VB, Bhigjee AI, Bill PLA, Connolly C. Cytokine patterns in HIV seropositive patients with tuberculous meningitis. J Neurol Neurosurg Psychiatry 2002; 73:598-9.
24. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with human immunodeficiency virus. New Eng J Med 1992; 326:668-72.
25. Dube MP, Holran PD, Larsen RA. Tuberculous meningitis with and without human immunodeficiency virus. Am J Med 1992; 93:520-4.
26. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998; 53:536-48.